Navigation Links
ArtJen Announces Major Clinical Trial of Its Patented Weight Loss Product FBCx
Date:9/19/2007

WINDSOR, Ontario, Sept. 19 /PRNewswire/ -- ArtJen Complexus Holdings Corp. (http://www.fbcx.com) today announced that, following the results of their clinical trial with obese type 2 diabetics and an animal study at the National Institutes of Health, FBCx is being studied by a major US west-coast university medical center. The largest study to date on the patented all- natural soluble fiber that binds dietary fat will involve overweight but not obese individuals.

"Our earlier study with obese, type 2 diabetics demonstrated significant weight loss when adjusted for changes in diet." said FBCx co-inventor, Dr. Catherine Jen. "It's time to look at the non-obese population segment that would benefit from losing 10-25 pounds."

"We expect this study will show FBCx to be an easy and effective aid for losing weight and for lowering elevated levels of blood fats," continued FBCx co-inventor, Dr. Joseph Artiss.

Previous FBCx study findings include:

-- Effective at reducing and/or maintaining body weight in patients with

type 2 diabetes.

-- Lowered both triglyceride and LDL (bad) cholesterol levels in patients

who began the study with elevated triglyceride levels.

-- Blood work findings indicate an insulin sensitivity increase and

therefore a possible delay in the need to institute or the intensity of

insulin therapy in type 2 diabetics.

-- FBCx was shown to bind and remove 9 times its own weight in dietary

fat, essentially preventing 80 calories from being absorbed per tablet.

-- FBCx appears to preferentially bind saturated over unsaturated dietary

fats.

-- FBCx produced no adverse side effects.

These findings and others have lead to FBCx being referred to as the "miracle weight loss" pill in media reports and by renowned members of the medical profession.

"We are so convinced of the efficacy of FBCx t
'/>"/>

SOURCE ArtJen Complexus Holdings Corp.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 19, 2013  Finesse Solutions, Inc, a manufacturer ... process applications, announced the launch of its new ... culture and fermentation.  The 3L glass vessels are ... Finesse bioreactors and are designed to optimize yield ... fully compatible with all Finesse G3Lab controllers, and ...
(Date:6/19/2013)...  Decision Resources, one of the world,s leading ... issues, finds that, for the treatment of rheumatoid ... rheumatologists cite a therapy,s induction of remission as ... prescribing decisions. Over 60 percent and 70 percent ... percentage of patients achieving remission at six months ...
(Date:6/19/2013)... , June 19, 2013   Nektar Therapeutics ... from a human abuse liability (HAL) study for NKTR-181, ... of entry into the brain.  This slow rate of entry ... the abuse of and addiction to current opioid analgesics. 1 ... was rated similar to placebo in "drug liking" and ...
Breaking Medicine Technology:Finesse Solutions Launches Next Generation SmartGlass 3L Bioreactors for Cell Culture and Fermentation 2U.S. and European Rheumatologists Agree That a Therapy's Induction of Remission is One of the Attributes That Most Influences Their Prescribing Decisions in Rheumatoid Arthritis 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9
... Texas, Oct. 4, 2011 Today, Children,s ... in the state and the only stand-alone facility between Dallas ... Earlier, hospital personnel used Scott & White,s state-of-the-art Simulation Center ... Hospital, which was housed in Scott & White Hospital-Temple, before ...
... OTCQX: RHHBY) announced plans today to expand its coagulation testing ... clinics with the development of a full line of coagulation ... expected to be introduced in the U.S. and Canada in ... Roche Diagnostics is the global market leader in coagulation ...
Cached Medicine Technology:Children's Hospital at Scott & White Opens 2Children's Hospital at Scott & White Opens 3Children's Hospital at Scott & White Opens 4Roche to Expand Coagulation Testing Portfolio, Develop New Systems for Diagnostic Laboratories in US and Canada by 2014 2
(Date:6/19/2013)... 2013 Maui'd Forever , Hawaii's ... being an effective and cost effective way to provide ... partnered up with Tom Barefoot’s Tours providing an activity ... of Hawaii’s activities. , They have just released a ... the lowest prices on their Hawaii activities. , ...
(Date:6/19/2013)... June 19, 2013 According to Transparency ... Market Share, Trends, Analysis and Forecast, 2011 – 2017,” ... billion in the year 2011 and is expected to ... CAGR of 9.7% from 2011 to 2017. Flexible endoscopes ... contributing about USD 2,201 million for the year 2011. ...
(Date:6/19/2013)... neurologists treating stroke victims has been "time equals brain." That,s ... receive a drug that dissolves the stroke-causing blood clot can ... saved or lost. , But specific information has ... intravenous drug known as a tissue plasminogen activator, or ... the most common type of stroke. , Now, ...
(Date:6/19/2013)... Il. A Loyola University Chicago Niehoff School of ... to study whether Vitamin D can improve mood in ... also will examine whether vitamin D supplementation can reduce ... diabetes. The grant is from the National Institute of ... Principal investigator Sue M. Penckofer, PhD, RN and colleagues ...
(Date:6/19/2013)... June 19, 2013 AquaPrint Solutions in Thomson, ... & Grub with a newly-designed Harley Davidson motorcycle gas tank. ... AquaPrint Solutions with an idea of taking a split tank ... ages and transforming it into a work of art. ... & Grub several toilet seats that had been dipped in ...
Breaking Medicine News(10 mins):Health News:Maui'd Forever Pleased to Offer Price Guarantee on Hawaii Activities 2Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 2Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 3Health News:Timely treatment after stroke is crucial, UCLA researchers report 2Health News:Timely treatment after stroke is crucial, UCLA researchers report 3Health News:Loyola receives $1.5 million grant to study vitamin D for diabetes and depression 2Health News:AquaPrint Solutions Transforms Harley Davidson Gas Tank into a Work Of Art for Poopy’s Pub & Grub 2
... a genetic disorder characterized by distorted, sickle shaped red blood ... organ damage to the kidneys, spleen, and liver. The sickle ... incidence is about 1 in 500., ,Despite much clinical ... Pain can be relieved, and the frequency and duration of ...
... a loss of memory due to their health condition, a ... their medications on time., ,In a study from Johns ... giving electronic-voice reminders to “take your medicine” proves to be ... slightly impaired by the virus., ,The investigators report that ...
... little fear or suspicion; it is perceived as a realm that ... // approach can be dangerous if they can affect public policy ... have a say in developing guidelines for dealing with certain scientific ... can and cannot be expected to do. This in turn, depends ...
... maybe daggers drawn on many issues, however one issue that ... India of 70 poor Pakistani children later this month for ... pave path towards many more similar gestures and result in ... sides of the border have failed to deliver in the ...
... bare metal stents, placement of stents that release ... artery re-narrowing nine months following angioplasty for patients ... article in the September 14 issue of JAMA. ... atherosclerotic coronary artery disease, according to background information ...
... encephalitis in Uttar Pradesh crossed 800 Saturday. But the administration ... be at the root of the virtual epidemic. ,The ... animal is known to be the biggest host for the ... ,Uttar Pradesh officials do not even have any official ...
Cached Medicine News:Health News:Hydroxyurea Treatment For Children With Sickle Cell Disease 2Health News:Memory-Aid To Help HIV Patients 2Health News:Scientists Awarded Appropriately For Contribution Towards Medical Research 2Health News:Surgeons in India to Mend ‘Pakistani Hearts’ by treating 70 Childr 2Health News:Stents That Release Medication To Check Artery Narrowing 2Health News:Pigs Population A Major Threat To Encephalitis Ravaged UP 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: